A Study of How the Body Breaks Down and Eliminates LY2623091

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This type of study is called a radiolabeled study. For this study, LY2623091 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radioactive form of the element, carbon. This study will increase understanding about how the drug appears in the blood, urine, and stool after it is administered to healthy participants. Information about any side effects that may occur will also be collected. This study will last up to 22 days for each participant, not including screening. Screening is required within 28 days prior to enrollment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants

NCT01913314

Healthy Volunteers

COMPLETED PHASE1

A Study of [¹⁴C]-LY3023414 in Healthy Participants

NCT02575703

Healthy

COMPLETED PHASE1

A Study of [¹⁴C]-LY3202626 in Healthy Male Participants

NCT02555449

Healthy

COMPLETED PHASE1

A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

NCT06052462

Healthy

COMPLETED PHASE1

A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants

NCT05749848

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY2623091

Single oral dose of LY2623091

Group Type EXPERIMENTAL

LY2623091

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2623091

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly healthy males; as determined by physical examination, clinical laboratory tests, medical history and electrocardiograms (ECGs).
* With a body mass index of 18.5 to 32.0 kilogram per square meter (kg/m\^2), inclusive.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes